Sign Up to like & get
recommendations!
1
Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2019-0114
Abstract: Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the…
read more here.
Keywords:
carcinoma;
lenvatinib elderly;
efficacy safety;
case ... See more keywords